NCT07243704: BEAT-ICH

Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage

Not yet recruiting Phase 3 Last updated 9 February 2026

What this trial tests

Phase 3 trial testing Aspirin 75 mg daily in Intracerebral Haemorrhage in 5,676 participants. Not yet recruiting.

Timeline

15 February 2026

Primary endpoint
14 February 2029

14 February 2029

Quick facts

Lead sponsor	Christian Medical College and Hospital, Ludhiana, India
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	5,676
Start date	15 February 2026
Primary completion	14 February 2029
Estimated completion	14 February 2029
Sites	40 locations across India

Drugs / interventions tested

• Aspirin 75 mg daily — full drug profile →
• Placebo

Conditions studied

• Intracerebral Haemorrhage — all drugs for Intracerebral Haemorrhage →

Sponsor

Christian Medical College and Hospital, Ludhiana, India

Who can join

Adults 18 to 99, any sex, with Intracerebral Haemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged ≥18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75 mg od) versus placebo for the entire duration of the trial for preventing MACE. Recruitment duration is for 2.5 years. The duration of the medication and follow-up will vary based on recruitment timeline. If recruited during the first year of the trial, the patient will take the medication for three years or until the trial ends or an event occurs, with a matching follow-up period. If recruited towards the end of the trial, he/she will take the medication for six months and be followed up for the same duration. The trial's follow-up duration is three years. The patients will be recruited for 2.5 years, and the last recruit will have a minimum follow-up of six months. No new patients will be recruited within the last six months of the trial, but all the patients will be followed up until the end of the trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.